RT Journal Article
SR Electronic
T1 Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.21.21258528
DO 10.1101/2021.06.21.21258528
A1 Feng, Shuo
A1 Phillips, Daniel J.
A1 White, Thomas
A1 Sayal, Homesh
A1 Aley, Parvinder K.
A1 Bibi, Sagida
A1 Dold, Christina
A1 Fuskova, Michelle
A1 Gilbert, Sarah C.
A1 Hirsch, Ian
A1 Humphries, Holly E.
A1 Jepson, Brett
A1 Kelly, Elizabeth J.
A1 Plested, Emma
A1 Shoemaker, Kathryn
A1 Thomas, Kelly M.
A1 Vekemans, Johan
A1 Villafana, Tonya L.
A1 Lambe, Teresa
A1 Pollard, Andrew J
A1 Voysey, Merryn
A1 the Oxford COVID Vaccine Trial Group
YR 2021
UL http://medrxiv.org/content/early/2021/06/24/2021.06.21.21258528.abstract
AB Background Although 6 COVID-19 vaccines have been approved by the World Health Organisation as of 16th June 2021, global supply remains limited. An understanding of the immune response associated with protection could facilitate rapid licensure of new vaccines.Methods Data from a randomised efficacy trial of ChAdOx1 nCoV-19 (AZD1222) vaccine in the UK was analysed to determine the antibody levels associated with protection against SARS-CoV-2. Anti-spike and anti-RBD IgG by multiplex immunoassay, pseudovirus and live neutralising antibody at 28 days after the second dose were measured in infected and non-infected vaccine recipients. Weighted generalised additive models for binary data were applied to symptomatic and asymptomatic SARS-CoV-2 infection data from ChAdOx1 nCoV-19 recipients. Cubic spline smoothed log antibody levels, and weights were applied to account for potential selection bias in sample processing. Models were adjusted for baseline risk of exposure to SARS-CoV-2 infection.Results Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. Vaccine efficacy of 80% against primary symptomatic COVID-19 was achieved with an antibody level of 40923 (95% CI: 16748, 125017) and 63383 (95% CI: 16903, not computed (NC)) for anti-spike and anti-RBD, and 185 (95% CI: NC, NC) and 247 (95% CI: 101, NC) for pseudo- and live-neutralisation assays respectively. Antibody responses did not correlate with overall protection against asymptomatic infection.Conclusions Correlates of protection can be used to bridge to new populations using validated assays. The data can be used to extrapolate efficacy estimates for new vaccines where large efficacy trials cannot be conducted. More work is needed to assess correlates for emerging variants.Competing Interest StatementOxford University has entered into a partnership with AstraZeneca for further development of ChAdOx1 nCoV-19. SCG is co-founder of Vaccitech (collaborators in the early development of this vaccine candidate) and named as an inventor on a patent covering use of ChAdOx1 vectored vaccines and a patent application covering this SARS-CoV-2 vaccine (PCT/GB2012/000467). TL is named as an inventor on a patent application covering this SARS-CoV-2 vaccine and was a consultant to Vaccitech for an unrelated project during the conduct of the study. AJP is chair of the UK Department of Health and Social Care (DHSC) Joint Committee on Vaccination & Immunisation (JCVI) but does not participate in discussions on COVID-19 vaccines, and is a member of WHO SAGE. AJP is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article do not necessarily represent the views of the DHSC JCVI NIHR or WHO. TW, HS, IH, JB, EJK, KS, JV, TLV are employees of AstraZeneca. The other authors declare no competing interests.Clinical TrialNCT04400838Funding StatementThis Article reports independent research funded by UK Research and Innovation, Coalition for Epidemic Preparedness Innovations,the National Institute for Health Research, and AstraZeneca. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), reference 21584/0428/001 0001, and the South-Central Berkshire Research Ethics Committee, reference 20/SC/0179.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised participant data will be made available when the trial is complete, upon request directed to the corresponding author. Proposals will be reviewed and approved by the sponsor, investigator, and collaborators on the basis of scientific merit. After approval of a proposal, data can be shared through a secure online platform after signing a data access agreement. All data will be made available for a minimum of 5 years from the end of the trial.